- CMO Dr. Udayan Guha's employment terminated effective October 31, 2026.
- Departure executed in contemplation of pending merger with Avere Therapeutics.
- Routine leadership restructuring ahead of corporate transaction close.
? Neutral AI Sentiment (-0.5 / 10)